Physician profile
Peter Friedman
NPI 1639158116
$28,656.70
in general payments reported to CMS, 2019-2025
9 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $749 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $6,685 · Food and Beverage: $1,449 · Travel and Lodging: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,400.00 |
| Consulting Fee | $6,685.00 |
| Food and Beverage | $1,448.50 |
| Travel and Lodging | $123.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $27,394.87 | 2025 | Nemluvio |
| Almirall LLC | $735.00 | 2024 | |
| Ucb, INC. | $208.88 | 2025 | Bimzelx |
| Incyte Corporation | $169.46 | 2025 | Opzelura |
| Leo Pharma INC. | $87.70 | 2025 | Anzupgo |
| Heartflow, INC. | $24.98 | 2025 | |
| Arcutis Biotherapeutics, INC. | $21.88 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $13.93 | 2024 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.